De Rose Domenico Umberto, Salvatori Guglielmo, Dotta Andrea, Auriti Cinzia
Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.
Viruses. 2022 Mar 5;14(3):539. doi: 10.3390/v14030539.
This systematic review summarizes current knowledges about maternal and neonatal outcomes following COVID-19 vaccination during pregnancy and breastfeeding. ( PubMed, Cochrane Library, and the Education Resources Information Center (ERIC) were searched up to 27 October 2021. The primary outcome was to estimate how many pregnant and lactating women were reported to be vaccinated and had available maternal and neonatal outcomes. Forty-five studies sourcing data of 74,908 pregnant women and 5098 lactating women who received COVID-19 vaccination were considered as eligible. No major side-effects were reported, especially during the second and third trimester of pregnancy and during breastfeeding. Conversely, available studies revealed that infants received specific SARS-CoV-2 antibodies after maternal vaccination. Vaccination against the SARS-CoV-2 virus should be recommended for pregnant women, after the pros and cons have been adequately explained. In particular, given the still limited evidence and considering that fever during the first months of gestation increases the possibility of congenital anomalies, they should be carefully counseled. The same considerations apply to breastfeeding women, also considering the immune responses that mRNA vaccines can generate in their human milk.
本系统评价总结了关于孕期和哺乳期接种新冠病毒疫苗后母婴结局的现有知识。（截至2021年10月27日，检索了PubMed、Cochrane图书馆和教育资源信息中心（ERIC）。主要结局是估计报告接种疫苗且有可用母婴结局的孕妇和哺乳期妇女数量。45项研究被认为符合条件，这些研究提供了74908名接种新冠病毒疫苗的孕妇和5098名哺乳期妇女的数据。未报告重大副作用，尤其是在妊娠中期和晚期以及哺乳期。相反，现有研究表明，母亲接种疫苗后婴儿会获得特定的新冠病毒抗体。在充分解释利弊后，建议孕妇接种新冠病毒疫苗。特别是，鉴于证据仍然有限，且考虑到妊娠头几个月发烧会增加先天性异常的可能性，应仔细为她们提供咨询。同样的考虑也适用于哺乳期妇女，同时也要考虑mRNA疫苗可能在她们的母乳中产生的免疫反应。
